Document Detail


Strategies to reduce bleeding among patients with ischemic heart disease treated with antiplatelet therapies.
MedLine Citation:
PMID:  19695364     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Antiplatelet therapy is the cornerstone of management in acute coronary syndromes (ACS) and percutaneous coronary intervention. Combination therapy with aspirin and clopidogrel reduces the risk of death, myocardial infarction, or stroke in ACS but increases the risk of major bleeding, which studies indicate is 1%-4% higher when clopidogrel is added to aspirin. Given the association between bleeding and adverse outcomes, minimizing bleeding risk is a clinical priority. This review outlines strategies to reduce both acute and chronic bleeding risk with aspirin and clopidogrel and focuses on dosing of concomitant therapies, vascular access techniques, and mitigating the bleeding risk associated with coronary artery bypass grafting surgery.
Authors:
Sunil V Rao
Related Documents :
12241124 - Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?
17067704 - Myocardial infarction complicating the initial phase of an ovarian stimulation protocol.
12039484 - Influence of prehospital administration of aspirin and heparin on initial patency of th...
17670664 - Should clopidogrel be stopped prior to urgent cardiac surgery?
7465844 - Thallium-201 myocardial redistribution imaging 24 hours following stress exercise.
15064104 - Mitral annular calcification is a predictor for incident atrial fibrillation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  104     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-21     Completed Date:  2009-09-15     Revised Date:  2010-07-07    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  60C-3C     Citation Subset:  AIM; IM    
Affiliation:
Duke Clinical Research Institute, Durham, NC 27705, USA. sunil.rao@duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / therapy*
Administration, Oral
Humans
Myocardial Revascularization / adverse effects
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects*
Postoperative Hemorrhage / etiology*,  prevention & control*
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors
Comments/Corrections
Erratum In:
Am J Cardiol. 2010 Jul 15;106(2):295

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transradial intervention for minimizing bleeding complications in percutaneous coronary intervention...
Next Document:  Opiate replacement therapy in France: assessment of the public policies